These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 33336213)

  • 1. Assessing Durability of Vaccine Effect Following Blinded Crossover in COVID-19 Vaccine Efficacy Trials.
    Follmann D; Fintzi J; Fay MP; Janes HE; Baden L; Sahly HE; Fleming TR; Mehrotra DV; Carpp LN; Juraska M; Benkeser D; Donnell D; Fong Y; Han S; Hirsch I; Huang Y; Huang Y; Hyrien O; Luedtke A; Carone M; Nason M; Vandebosch A; Zhou H; Cho I; Gabriel E; Kublin JG; Cohen MS; Corey L; Gilbert PB; Neuzil KM
    medRxiv; 2020 Dec; ():. PubMed ID: 33336213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated.
    Follmann D; Fintzi J; Fay MP; Janes HE; Baden LR; El Sahly HM; Fleming TR; Mehrotra DV; Carpp LN; Juraska M; Benkeser D; Donnell D; Fong Y; Han S; Hirsch I; Huang Y; Huang Y; Hyrien O; Luedtke A; Carone M; Nason M; Vandebosch A; Zhou H; Cho I; Gabriel E; Kublin JG; Cohen MS; Corey L; Gilbert PB; Neuzil KM
    Ann Intern Med; 2021 Aug; 174(8):1118-1125. PubMed ID: 33844575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing vaccine durability in randomized trials following placebo crossover.
    Fintzi J; Follmann D
    Stat Med; 2021 Nov; 40(27):5983-6007. PubMed ID: 33928660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating the Long-term Efficacy of Coronavirus Disease 2019 (COVID-19) Vaccines.
    Lin DY; Zeng D; Gilbert PB
    Clin Infect Dis; 2021 Nov; 73(10):1927-1939. PubMed ID: 33693529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating the Long-Term Efficacy of COVID-19 Vaccines.
    Lin DY; Zeng D; Gilbert PB
    medRxiv; 2021 Mar; ():. PubMed ID: 33501467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Hardt K; Vandebosch A; Sadoff J; Le Gars M; Truyers C; Lowson D; Van Dromme I; Vingerhoets J; Kamphuis T; Scheper G; Ruiz-Guiñazú J; Faust SN; Spinner CD; Schuitemaker H; Van Hoof J; Douoguih M; Struyf F;
    Lancet Infect Dis; 2022 Dec; 22(12):1703-1715. PubMed ID: 36113538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 vaccine trials: The potential for "hybrid" analyses.
    Fleming TR; Nason M; Krause PR; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Aug; 18(4):391-397. PubMed ID: 34041932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durability of Protection Against COVID-19 Through the Delta Surge for the NVX-CoV2373 Vaccine.
    Follmann D; Mateja A; Fay MP; Magaret CA; Huang Y; Fong Y; Angier H; Nason M; Gay CL; Kotloff K; Woo W; Cho I; Dunkle LM
    Clin Infect Dis; 2024 Jul; 79(1):78-85. PubMed ID: 38372392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
    Fleming TR; Krause PR; Nason M; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Jun; 18(3):335-342. PubMed ID: 33535811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of vaccine efficacy for variants that emerge after the placebo group is vaccinated.
    Follmann D; Fay M; Magaret C
    Stat Med; 2022 Jul; 41(16):3076-3089. PubMed ID: 35396728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.
    Toback S; Galiza E; Cosgrove C; Galloway J; Goodman AL; Swift PA; Rajaram S; Graves-Jones A; Edelman J; Burns F; Minassian AM; Cho I; Kumar L; Plested JS; Rivers EJ; Robertson A; Dubovsky F; Glenn G; Heath PT;
    Lancet Respir Med; 2022 Feb; 10(2):167-179. PubMed ID: 34800364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating Vaccine Efficacy Against SARS-CoV-2 Infection.
    Lin DY; Gu Y; Zeng D; Janes HE; Gilbert PB
    medRxiv; 2021 Apr; ():. PubMed ID: 33880481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating Vaccine Efficacy Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    Lin DY; Gu Y; Zeng D; Janes HE; Gilbert PB
    Clin Infect Dis; 2022 Feb; 74(3):544-552. PubMed ID: 34260716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.
    Áñez G; Dunkle LM; Gay CL; Kotloff KL; Adelglass JM; Essink B; Campbell JD; Cloney-Clark S; Zhu M; Plested JS; Roychoudhury P; Greninger AL; Patel N; McGarry A; Woo W; Cho I; Glenn GM; Dubovsky F;
    JAMA Netw Open; 2023 Apr; 6(4):e239135. PubMed ID: 37099299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial.
    Halperin SA; Ye L; MacKinnon-Cameron D; Smith B; Cahn PE; Ruiz-Palacios GM; Ikram A; Lanas F; Lourdes Guerrero M; Muñoz Navarro SR; Sued O; Lioznov DA; Dzutseva V; Parveen G; Zhu F; Leppan L; Langley JM; Barreto L; Gou J; Zhu T;
    Lancet; 2022 Jan; 399(10321):237-248. PubMed ID: 34953526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.